Akmez Latona: Clauss vs PT-Derived Fibrinogen in Relation to Viscoelastic Clot Strength
Akmez Latona, Specialist Emergency Physician at Queensland Health, reposted from RPTH Journal on LinkedIn:
”Coagulation profiles in Queensland Health report two fibrinogen measures: Clauss and PT-derived.
A novel aspect we introduced is the comparison of Clauss and PT-derived fibrinogen with viscoelastic clot firmness (ROTEM FIBTEM A5) across different domains of coagulopathy.
The findings show these tests are not interchangeable in context of low clot firmness and inform recommendations for fibrinogen reporting in critical bleeding within laboratory workflows.
Thank you Emergency Medicine Foundation – Australasia (EMF) for funding this study!”
RPTH Journal shared on LinkedIn about a recent article by Akmez Latona et al, adding:
”Fibrinogen testing in critical bleeding: Clauss or PT-derived, does it matter?
Two common assays are used to measure Fibrinogen: the Clauss method (Fib-C), considered the laboratory gold standard, and the prothrombin time-derived assay (Fib-D), a faster and cheaper alternative.
But are they interchangeable?
A new study in RPTH Journal compared both methods against viscoelastic clot firmness (ROTEM FIBTEM-A5) across all Queensland Health hospitals, using over 2,200 paired results from 2019 to 2025.
Key findings:
- Fib-C correlated more strongly with FIBTEM-A5 than Fib-D
- Fib-C showed higher accuracy for detecting critically low clot firmness
- Fib-D systematically overestimated fibrinogen levels compared with Fib-C – in trauma, chronic liver disease, and overall
The clinical implication is clear: in critical bleeding, Fib-C better reflects true clot firmness, and routine Fib-D reporting may be misleading rather than helpful.”
Title: Diagnostic accuracy of Clauss and prothrombin time–derived fibrinogen against rotational thromboelastometry FIBTEM-A5
Authors: Akmez Latona, Kate Hill, Mark Rane, Alan Ho, Biswadev Mitra
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn RuksakulpiwatÖ‰ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin